Sugi Predict

Sugi Predict / Compounds / SCHEMBL2037513

SCHEMBL2037513

SCHEMBL2037513

C[C@@H](N)c1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 6/20 0.62
▸ ESR2 Q92731 5/20 0.62
▸ PDCD1 Q15116 1/20 0.62
▸ CD274 Q9NZQ7 1/20 0.62
▸ ADRB2 P07550 1/20 0.56
▸ TAAR1 Q96RJ0 5/20 0.50
▸ SLC6A2 P23975 2/20 0.50
▸ ALOX15 P16050 3/20 0.48
▸ LMNA P02545 2/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ MAPT P10636 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ PGR P06401 1/20 0.48
▸ CHRM2 P08172 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.48
▸ AR P10275 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CHRM1 P11229 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032476 1.00 ESR1 (0.62) ESR1ESR2PDCD1CD274ADRB2
SCHEMBL633374 1.00 ESR1 (0.62) ESR1ESR2PDCD1CD274ADRB2
Bromide SCHEMBL23672238 0.97 ESR1 (0.59) ESR1ESR2PDCD1CD274ADRB2
Hydrochloric Acid SCHEMBL3178913 0.97 ESR1 (0.59) ESR1ESR2PDCD1CD274ADRB2
Bromide SCHEMBL15901678 0.97 ESR1 (0.59) ESR1ESR2PDCD1CD274ADRB2
Bromide SCHEMBL4909882 0.97 ESR1 (0.59) ESR1ESR2PDCD1CD274ADRB2
Hydrochloric Acid SCHEMBL14830851 0.97 ESR1 (0.59) ESR1ESR2PDCD1CD274ADRB2
Iodide SCHEMBL29068279 0.97 ESR1 (0.59) ESR1ESR2PDCD1CD274ADRB2
Hydrochloric Acid SCHEMBL8702706 0.97 ESR1 (0.59) ESR1ESR2PDCD1CD274ADRB2
SCHEMBL18664397 0.93 ESR1 (0.54) ESR1ESR2PDCD1CD274ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 — — US disclosed
CN-120624322-A Production method of p-hydroxyacetophenone 杭州唯铂莱生物科技有限公司 2025-09-12 — — CN disclosed
WO-2023129564-A1 DEGRADERS OF GRK2 AND USES THEREOF CYGNAL THERAPEUTICS, INC. (US) 2023-07-06 — — WO disclosed
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2022-10-04 — — US disclosed
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2022-10-04 — — US disclosed
EP-3707136-B1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2022-05-04 — — EP disclosed
US-20210230148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2021-07-29 — — US disclosed
EP-3356348-B1 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS SENTINEL ONCOLOGY LTD (GB) 2021-05-05 — — EP disclosed
CN-108473472-B 2-aminoquinazoline derivatives as P70S6kinase inhibitors 圣提内尔肿瘤学有限公司 2021-02-12 — — CN disclosed
US-10730882-B2 2-aminoquinazoline derivatives as P70S6 kinase inhibitors SENTINEL ONCOLOGY LIMITED (GB) 2020-08-04 — — US disclosed
US-20060178366-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2006-08-10 — — US disclosed
WO-2005121130-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2005-12-22 — — WO disclosed
EP-1017672-B1 NEW NPY ANTAGONISTS ASTRAZENECA AB (SE) 2002-11-27 — — EP disclosed
US-6127414-A NPY antagonists ASTRA AKTIEBOLAG (SE) 2000-10-03 — — US disclosed
EP-1017672-A1 NEW NPY ANTAGONISTS AstraZeneca AB (SE) 2000-07-12 — — EP disclosed
WO-1999018948-A1 NEW USE OF NPY ANTAGONISTS ASTRA AKTIEBOLAG (SE) 1999-04-22 — — WO disclosed
WO-1999015498-A1 NEW NPY ANTAGONISTS ASTRAZENECA AB (SE) 1999-04-01 — — WO disclosed
US-4904680-A IMMUNOLOGY SANKYO COMPANY, LIMITED (JP) 1990-02-27 — — US disclosed
EP-0173441-B1 AMINO ACID DERIVATIVES HAVING ANTI-TUMOR ACTIVITY AND COMPOSITIONS CONTAINING THEM SANKYO COMPANY LIMITED (JP) 1990-01-24 — — EP disclosed
EP-0173441-A1 Amino acid derivatives having anti-tumor activity and compositions containing them SANKYO COMPANY LIMITED (JP) 1986-03-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof TPMT, TET1, TET2 ESR1 4059/4885ESR2 3488/4885PDCD1 4798/4885
US-20060178366-A1 Compounds for the treatment of inflammatory disorders MMP12, ADAMTS1, TNF ESR1 2463/4885ESR2 1635/4885PDCD1 2581/4885
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A ESR1 3453/4885ESR2 941/4885PDCD1 3750/4885
US-10730882-B2 2-aminoquinazoline derivatives as P70S6 kinase inhibitors RPS6KA1, MTOR, RPTOR ESR1 2166/4885ESR2 1321/4885PDCD1 3712/4885
US-20210230148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TPMT, TET1, TET2 ESR1 4059/4885ESR2 3488/4885PDCD1 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.